Their investigation began with only a tiny blood platelet, but quickly they discovered opportunities for growth and expanding the breadth of the research. “We have a lot to gain by looking at platelets and how they influence cancer and healing,” said Dr. Camillo Bulla. …
Pulmonary hypertension is caused by the narrowing of the blood vessels in the lung, due to excessive growth of cells in the blood vessel wall. The cells grow in number until they obstruct the vessels, causing the heart to struggle pushing blood through the lungs to the point where the heart fails and the patient dies…
In research published today in the American Journal of Gastroenterology, Murray Korc, M.D., the Myles Brand Professor of Cancer Research at the Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, and colleagues found that several microRNAs — small RNA molecules — circulate at high levels in the blood of pancreatic cancer patients. “This is a new finding that extends previous knowledge in this field,” Dr. Korc said. …
The research reveals that women who consume foods containing flavonols and flavanones (both subclasses of dietary flavonoids) significantly decrease their risk of developing epithelial ovarian cancer, the fifth-leading cause of cancer death among women. The research team studied the dietary habits of 171,940 women aged between 25 and 55 for more than three decades. The team found that those who consumed food and drinks high in flavonols (found in tea, red wine, apples and grapes) and flavanones (found in citrus fruit and juices) were less likely to develop the disease. Ovarian cancer affects more than 6,500 women in the UK each year…
But a cunningly simple new device can stop that vital information from “going to waste.” Brigham Young University chemist Adam Woolley and his students made a device that can detect markers of kidney disease and prostate cancer in a few minutes. All you have to do is drop a sample into a tiny tube and see how far it goes…
“Bortezomib helped a group of patients who desperately needed a treatment, having failed multiple different therapies,” said UC Davis hematologist and associate professor Mehrdad Abedi, lead author on the paper. “The drug fights chronic graft-versus host disease, and unlike other GVHD therapies such as steroid, cyclosporine or mycophenolate, it treats chronic GVHD without dampening the graft-versus-tumor effect, which can be critically important to help patients avoid relapse. In fact, because bortezomib is an anti-cancer drug, it potentially attacks cancer cells in its own right.” The trial results were published in October in the journal Blood. Chronic GVHD strikes patients who have received stem cell transplants from donors, commonly called allogeneic transplants. …
The Duke researchers shared their findings at the Palliative Care in Oncology Symposium sponsored by the American Society of Clinical Oncology. In the new treatment model, medical oncologists and palliative care physicians partnered in a “co-rounding” format to deliver cancer care for patients admitted to Duke University Hospital’s solid tumor unit. The Duke model fostered collaboration and communication between the specialists, who met several times a day to discuss patient care…
The immune system defends the body from infections and can also spot and destroy cancer cells. Lymph nodes are at the heart of this response, but until now it has never been explained how they expand during disease. The researchers — at Cancer Research UK’s London Research Institute — found that when a type of immune cell, called dendritic cells, recognises a threat they make a molecule called CLEC-2 that tells the cells lining the lymph nodes to stretch out and expand to allow for an influx of disease fighting cells. It’s long been known that these same dendritic cells patrol the body searching for threats and call for reinforcements to tackle them…
Glioblastoma is the most common and deadliest form of brain cancer. The majority of these tumors – known as primary glioblastomas – occur in the elderly without evidence of a less malignant precursor. …
Treatments for retinoblastoma have progressed dramatically in recent years, one being a procedure called ophthalmic artery infusion chemotherapy. A tiny catheter is inserted into an artery that provides blood flow (and chemotherapy) directly to the eye and tumor. Originally introduced in the late 1980s, direct ophthalmic artery infusion significantly increases treatment effectiveness while reducing side effects. Unfortunately, many children with retinoblastoma are not good candidates for conventional ophthalmic artery infusion — in particular younger, smaller patients with advanced disease, according to Todd Abruzzo, MD, director of Interventional Neuroradiology at Cincinnati Children’s. …